#China #Shanghai #Antengene #Autoimmune Diseases #ATG-207

Antengene Unveils Preclinical Results of ATG-207 at ACR 2026

Antengene Corporation Limited, a notable biopharmaceutical company listed on the SEHK (6996.HK), made headlines at the American College of Rheumatology (ACR) Annual Meeting 2026 with their latest findings on the preclinical development of ATG-207, an αCD3-TGF-β bifunctional fusion protein. This innovative therapy is being devised to treat T cell-mediated autoimmune diseases, and its presentation generated significant interest among attendees in the research community.

Overview of ATG-207

ATG-207 is positioned as a globally first-in-class agent designed to target T cell-driven autoimmune conditions. The underlying issue in these diseases is the imbalance resulting from out-of-control effector T cells and insufficient regulatory T cell (Treg) function, leading to a breakdown in immune tolerance. Current therapies often fail to restore this balance, raising significant clinical concerns. Therefore, a new approach such as ATG-207, which focuses on regulatory T cell induction, could provide a pivotal shift in treatment strategies.

Transforming growth factor-beta (TGF-β) plays a crucial role in the differentiation and maintenance of Tregs, yet its widespread application in treatments is limited due to safety issues related to systemic delivery. The design of ATG-207 combats this challenge by utilizing a peptide-masked, TGFβRIII-biased TGF-β domain linked to an anti-CD3 antibody. This novel configuration allows for precise targeting of T cells, confining the action of TGF-β signaling and minimizing undesirable side effects associated with broader receptor engagement.

Key Findings from the Presentation

The findings presented included detailed information about the binding affinity of ATG-207 to different TGF-β receptors, assessed through surface plasmon resonance (SPR). Notably, ATG-207 showed a marked preference for TGFβRIII over TGFβRII, indicating its potential for targeted therapy. The study revealed that ATG-207 exhibits a significantly reduced binding affinity—100-fold less—compared to the unmasked TGF-β, suggesting a strategic advantage in preventing off-target activity.

Furthermore, when tested in vitro, ATG-207 successfully induced functional iTreg cells from CD4⁺ T cells of various donors, as confirmed by flow cytometry that measured FOXP3 expression and verified the phenotypic traits of these iTregs. These cells exhibited a significant capacity to suppress T cell proliferation, underscoring ATG-207's immunosuppressive potential.

Additionally, in preclinical models, including experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease (IBD), ATG-207 demonstrated robust therapeutic efficacy. Both mouse models using humanized CD3 T cells validated the compound's safety profile without adverse effects observed during toxicology assessments.

Conclusion

The results shared at ACR 2026 indicate that ATG-207 combines effective modulation of T cells with TGFβRIII-biased signaling that could facilitate the re-establishment of immune tolerance in T cell-mediated autoimmune diseases. Given the high demand for novel therapies in this domain, such promising preliminary findings from Antengene could pave the way for new treatment paradigms.

Antengene Corporation remains committed to addressing significant unmet medical needs, with a pipeline that includes multiple investigational candidates engaging in innovative therapeutic pathways. The implications of ATG-207 could be broad-reaching, potentially revolutionizing the management of autoimmune disorders and restoring balance in the immune system.

About Antengene Corporation

Antengene Corporation Limited is known for its dedication to advancing the field of biotechnology by developing first-in-class therapeutics for serious diseases. With a diverse pipeline spanning various stages of clinical development, Antengene continues to focus on innovative strategies that align with their mission of transforming patient care through scientific advancement.